ACS Dobfar SpA – FDA 483
An FDA inspection of ACS Dobfar SpA in Albano S.A. (BG) Italy revealed significant deficiencies in operator qualification and quality control processes. Operators performing critical in-process control testing had not been re-evaluated or re-qualified for years, and one was observed making imprecise measurements during sample preparation. Furthermore, the firm failed to initiate corrective actions for persistent operator error trends identified in 2022 and continuing into 2023, indicating a systemic issue with quality oversight.
- Company
- ACS Dobfar SpA
- Product type
- drugs
ID · 4a7b5e7b-a820-4d20-ae40-8178f3b46d0a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.